Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer

    NEXT STORY
    Turning Point Therapeutics Announces Program Updates and Milestones for 2020
    PREV STORY
    Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    VBL Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29

    TEL AVIV, Israel, Nov. 23, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    LIDDS completes a direct share issue raising SEK 9.0 million

    author_avatar
    NASDAQ Market News

    VALNEVA Announces its Intention to Delist from the Vienna Stock Exchange

    Valneva Announces its Intention to Delist from the Vienna Stock Exchange  Trading will be ...

    author_avatar
    NASDAQ Market News